(Total Views: 648)
Posted On: 05/11/2017 9:44:16 AM
Post# of 25602
$CBIS To enroll in this observational study, please contact Moonlight Cannabis Dispensary, located at 5801 E. Beverly Boulevard, Suite 100, Los Angeles, CA 90022. The dispensary's telephone number is 323.834.9420, and the email address is moonlightbeverly@gmail.com.
"The release of CBIS' Unisex Suppository Regimen is an important milestone as we build the company's portfolio of cannabinoid-based medicines. While this regimen is intended for men and women, we expect to release gender-specific suppositories and other products in the near future," stated Mr. Raymond C. Dabney, CBIS' President & CEO and Co-founder.
http://www.marketwired.com/press-release/cann...215769.htm
"The release of CBIS' Unisex Suppository Regimen is an important milestone as we build the company's portfolio of cannabinoid-based medicines. While this regimen is intended for men and women, we expect to release gender-specific suppositories and other products in the near future," stated Mr. Raymond C. Dabney, CBIS' President & CEO and Co-founder.
http://www.marketwired.com/press-release/cann...215769.htm
(0)
(0)
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
